Aldeyra Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

Aldeyra Therapeutics is a biotechnology research company focused on discovering and developing therapies for immune‑mediated diseases, aiming to modulate immunological systems to influence multiple pathways while minimizing toxicity. The company is based in Lexington, Massachusetts, at 131 Hartwell Avenue, Suite 320, and employs between 11 and 50 people. Its lead candidates, reproxalap and ADX‑629, target pre-cytokine mediators of inflammation known as reactive aldehyde species (RASP); reproxalap is in Phase 3 trials for dry eye disease and allergic conjunctivitis, while ADX‑629 is in Phase 2 proof‑of‑concept trials for psoriasis, asthma, and COVID‑19. The pipeline also includes ADX‑2191, an intravitreal methotrexate formulation at 0.8%, in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. The company has reported funding of about $125 million.

Sign up for free to view info

Email Format Employee directory